Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'
- PMID: 29092852
- DOI: 10.1136/annrheumdis-2017-212579
Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'
Keywords: anti-TNF; epidemiology; pharmacokinetics; rheumatoid arthritis.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. Ann Rheum Dis. 2018. PMID: 29133475 No abstract available.
Comment on
-
Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22. Ann Rheum Dis. 2018. PMID: 28939629 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
